AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
2
The man who helped build Palo Alto’s Cortex is leaving the company
3
Serbia opens Israeli drone factory as defense ties with Elbit deepen
4
“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B
5
Five months old, Noetive raises $41 million Seed to build AI for the physical economy
More news

Pharmaceuticals

20 stories about Pharmaceuticals
חברת השילוח הבינלאומית DSV משאית

One warehouse mistake allegedly turned $2.1M of drugs into a total loss

31.08.26|Hofit Cohen Olai
Harel is suing DSV after it says medicines worth €1.76 million were exposed to temperatures outside their permitted range for nearly 175 hours and ultimately had to be destroyed
ריצרד פרנסיס נשיא ו מנכל טבע

Teva posts strong revenue growth as branded drugs surpass $1 billion, despite acquisition-driven loss

29.07.26|Sophie Shulman
Revenue beats expectations and outlook improves, even as the Emalex acquisition pushes the company to a quarterly loss.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva’s search for a TAPI buyer ends in more job cuts

11.06.26|Sophie Shulman
Neot Hovav facility faces another round of reductions as sale prospects fade.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva beats estimates but cuts profit outlook after Emalex deal

29.04.26|Sophie Shulman
Strong Austedo growth offsets generics weakness as margins face acquisition-related pressure.
פרופ' אדי ברקאי ו ד"ר איריס ראובני

Israeli startup seeks to redefine PTSD treatment with novel brain mechanism

22.03.26|Shahar Ilan
Kailo Pharma’s approach aims to weaken traumatic memories without affecting normal recall.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva secures $400 million from Blackstone to advance flagship IBD drug

04.03.26|Sophie Shulman
The funding bolsters late-stage development of Duvakitug as the company races toward a $30 billion market.
נשיא ומנכ"ל טבע ריצ'רד פרנסיס

After a threefold rally, Teva faces its next test

29.01.26|Sophie Shulman
Innovative drugs surge, but 2026 forecasts revive investor doubts.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva’s 2026 forecast disappoints despite strong finish to 2025

28.01.26|Sophie Shulman
Lower revenue guidance overshadows rapid growth in branded drugs.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva bets on vitiligo drug in deal worth up to $500 million

12.01.26|Sophie Shulman
Agreement with Royalty Pharma underscores shift toward branded medicines.
המטה הגלובלי של חברת טבע בת"א

Teva’s branded drugs spark investor optimism

06.11.25|Sophie Shulman
The pharmaceutical company recorded its 11th consecutive quarter of growth, with revenue of $4.5 billion, thanks to sales of its brand-name drugs Austedo, Ajovy and Uzedy, which jumped 33%.
ריצ'רד פרנסיס מפגש העיתונאים

Teva shares soar on strong third-quarter performance

05.11.25|Sophie Shulman
Revenue climbs 3% to $4.5 billion, exceeding analysts’ expectations.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva returns to profit in Q2 but misses on revenue

30.07.25|Sophie Shulman
Austedo disappoints, while Uzedy and Ajovy drive upside in brand-name drugs.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s quiet layoff announcement reveals bold restructuring plan

08.05.25|Sophie Shulman
CEO signals this is ‘just the first step’ in multi-year effort to streamline and scale.
מנכ"ל טבע ריצ'רד פרנסיס מפגש עיתונאים 2025

Teva to cut 3,000 jobs by 2027 in drive toward higher profit margins

07.05.25|Sophie Shulman
Pharma giant targets 30% operating margin by laying off approximately 8% of its global workforce as it boosts forecasts on drug sales and updates its "Pivot to Growth" strategy. 
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva signals return to fundraising after decade-long crisis

08.02.25|Sophie Shulman
Israeli pharmaceutical giant eyes stock offering as part of its recovery plan.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook

30.01.25|Sophie Shulman
Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman
Duvakitug signals a brighter future for the Israeli pharma giant. 
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman
Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman
Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.
ריצ'רד פרנסיס נשיא ו מנכ"ל חברת טבע

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman
Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.
More Articles